Showing 100,701 - 100,720 results of 104,233 for search '(( 2 w decrease ) OR ( 5 ((((step decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.59s Refine Results
  1. 100701
  2. 100702
  3. 100703
  4. 100704
  5. 100705
  6. 100706
  7. 100707
  8. 100708
  9. 100709

    <i>ilys-3</i> is required in the pharynx and in the intestine to prevent bacterial burden in the gut lumen and to protect against <i>M</i>. <i>nematophilum</i>. by Maria João Gravato-Nobre (2941827)

    Published 2016
    “…<p><b>2.</b> (A) Images of a wild-type, <i>ilys-3</i> and <i>ilys-3; eEx752</i> one-day old adults fed for 24 hour on <i>E</i>. …”
  10. 100710

    Image_1_T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer.tif by Lirong Wu (3512831)

    Published 2021
    “…All patients received definitive SBRT to a biologically effective dose of >=100 Gy. The number of unique TCR clones was decreased after SBRT versus before, but clonality and the Shannon Entropy did not change. …”
  11. 100711

    Image_4_T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer.tif by Lirong Wu (3512831)

    Published 2021
    “…All patients received definitive SBRT to a biologically effective dose of >=100 Gy. The number of unique TCR clones was decreased after SBRT versus before, but clonality and the Shannon Entropy did not change. …”
  12. 100712

    Image_3_T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer.tif by Lirong Wu (3512831)

    Published 2021
    “…All patients received definitive SBRT to a biologically effective dose of >=100 Gy. The number of unique TCR clones was decreased after SBRT versus before, but clonality and the Shannon Entropy did not change. …”
  13. 100713

    Image_2_T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer.tif by Lirong Wu (3512831)

    Published 2021
    “…All patients received definitive SBRT to a biologically effective dose of >=100 Gy. The number of unique TCR clones was decreased after SBRT versus before, but clonality and the Shannon Entropy did not change. …”
  14. 100714

    Table_1_T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer.docx by Lirong Wu (3512831)

    Published 2021
    “…All patients received definitive SBRT to a biologically effective dose of >=100 Gy. The number of unique TCR clones was decreased after SBRT versus before, but clonality and the Shannon Entropy did not change. …”
  15. 100715

    Genome-wide complementary agonist and antagonist screens of host-encoded miRNAs impacting henipavirus infection at BSL-4. by Chwan Hong Foo (2571913)

    Published 2016
    “…(B and C) Results from the miRNA agonist (B) and antagonist (C) screens, with miRNAs ranked using a robust Z-score approach, from lowest (decreased virus infection) to highest (increased virus infection). …”
  16. 100716
  17. 100717

    DataSheet_1_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.docx by Hongyan Cheng (445898)

    Published 2021
    “…We found that 6B11-OCIK treatment was safe and well tolerated after five cycles of intravenous infusion with an initial dose of 1–2×10<sup>9</sup> cells and a dose-climbing strategy. …”
  18. 100718
  19. 100719

    Image_1_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.tif by Hongyan Cheng (445898)

    Published 2021
    “…We found that 6B11-OCIK treatment was safe and well tolerated after five cycles of intravenous infusion with an initial dose of 1–2×10<sup>9</sup> cells and a dose-climbing strategy. …”
  20. 100720

    Image_3_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.tif by Hongyan Cheng (445898)

    Published 2021
    “…We found that 6B11-OCIK treatment was safe and well tolerated after five cycles of intravenous infusion with an initial dose of 1–2×10<sup>9</sup> cells and a dose-climbing strategy. …”